Gregory Vidal is an Oncology physician affiliated with West Cancer Center. OpenAlex indexes 218 publications with 3,136 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7945 Wolf River Blvd
Germantown, TN 381381762
Telephone
901-683-0055Registry record last updated 8 Nov 2017.
Clinical trials
- Niraparib and Dostarlimab in HRD Solid Tumors
Sponsor: West Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202538 payments$21,300openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202516 payments$15,950openpaymentsdata.cms.gov ↗
- Genentech, Inc.Program year202513 payments$12,092openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.1%PD-1 inhibitor16.4%Pembrolizumab100%Part B, office-administered≥28 patientsPlatinum-based Drug14.7%Oxaliplatin98%Carboplatin2%Part B, office-administered≥17 patients+ 7 more classes in this area
Blood & clotting
32.6%Erythropoiesis-stimulating Agent18.1%Darbepoetin alfa100%Part B, office-administered≥33 patientsIron, parenteral preparations14.5%Ferric carboxymaltose100%Part B, office-administered≥13 patients+ 1 more class in this area
Musculoskeletal
6.1%RANK Ligand Inhibitor5.9%Denosumab99%Xgeva1%Part D + Part B<11 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥16 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ari Vanderwalde, MD
West Cancer Center
Daniel Vaena, MD
West Cancer Center
David Portnoy, MD
West Cancer Center
Noam Vanderwalde, MD
West Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”